Moderna Jumps Nearly 50% in January on Cancer Vaccine Buzz, Eyes 2026 Growth
Moderna rallied nearly 50% in January, doubling from November lows after plunging 95% from its 2021 peak, driven by Cramer’s spotlight on its personalized cancer vaccines and a forecast for 2026 revenue growth announced at its November investor day. The company remains unprofitable with no break-even timeline.
1. Strong January Rally
Moderna climbed nearly 50% in January, nearly doubling from its November lows after a prior 95% drop from its 2021 peak, reflecting renewed investor confidence following a positive November investor day.
2. Personalized Cancer Vaccine Prospects
Jim Cramer highlighted the buzz around Moderna’s long-promised personalized cancer vaccines, a potential breakthrough that investors view as a key growth catalyst.
3. Return to Revenue Growth Forecast
At its November investor day, Moderna projected a return to revenue growth in 2026, marking its first annual increase since 2021 and signaling a shift in its financial trajectory.
4. Profitability and Industry Context
Despite the rally and growth forecast, Moderna remains deeply unprofitable with no clear timeline to break even, and faces competition from other biotech firms that some analysts currently favor.